CSPC PHARMA (01093): Ulinastatin Injection Obtains Approval from National Medical Products Administration for Market Launch.

CSPC PHARMA (01093) announced that the ustekinumab injection (trade name: EniCk) developed by the group has been approved for marketing by the China National Medical Products Administration. This product is a fully human IgG1 monoclonal antibody that can bind with high affinity and specificity to the p40 protein subunits of human interleukin IL-12 and IL-23. IL-12 and IL-23 are naturally occurring cytokines that play a central role in the pathogenesis of plaque psoriasis and Crohn's disease inflammation and immune response processes. Ustekinumab monoclonal antibody disrupts IL-12 and IL-23 mediated signaling and cytokine cascade reactions by blocking interaction with the IL-12R1 receptor chain on the cell surface, effectively relieving disease symptoms and continuously improving the condition, bringing long-term clinical benefits to patients.